Pyxis' FY25 Net Loss Expands; Expects To Report Updated MICVO Phase 1 Monotherapy Data In Mid 2026

Pyxis Oncology reported an expanded net loss for full-year 2025 versus the prior year (the release did not disclose a dollar amount) and provided near-term clinical milestones for its lead investigational candidate, MICVO, in solid tumors. The update raises near-term cash-burn and dilution concerns while outlining potential catalyst events tied to upcoming MICVO development milestones.

Analysis

Pyxis Oncology reported an expanded net loss for full-year 2025 versus the prior year (the release did not disclose a dollar amount) and provided near-term clinical milestones for its lead investigational candidate, MICVO, in solid tumors. The update raises near-term cash-burn and dilution concerns while outlining potential catalyst events tied to upcoming MICVO development milestones.